|

Apalutamide (Erleada™) 60 mg or 240 mg tablets Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • ORIC Pharmaceuticals1
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS1

Indications

  • Cancer2
  • Castrate Sensitive Prostate Cancer1
  • Metastatic Prostate Cancer1
  • Metastatic Cancer1
  • Prostate Cancer1

Other1 trial

PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer

Colorado Springs, Colorado1 trial

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Rocky Mountain Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.